WallStreetZenWallStreetZen

NASDAQ: BDTX
Black Diamond Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BDTX

Based on 4 analysts offering 12 month price targets for Black Diamond Therapeutics Inc

Min Forecast
$11.00+356.43%
Avg Forecast
$15.50+543.15%
Max Forecast
$20.00+729.88%

Should I buy or sell BDTX stock?

Based on 4 analysts offering ratings for Black Diamond Therapeutics Inc.

Strong Buy
Strong Buy
1 analysts 25%
Buy
3 analysts 75%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although BDTX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates BDTX as a "Hold". Stocks with a Zen Rating of Hold have beat the market by +7.53%. Learn More

Be the first to know when Wall Street analysts revise their BDTX stock forecasts and price targets.

BDTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-11-06
lockedlocked$00.00+00.00%2024-10-08
lockedlocked$00.00+00.00%2024-09-23
lockedlocked$00.00+00.00%2024-07-31

1 of 1

Forecast return on equity

Is BDTX forecast to generate an efficient return?

Company
-90.84%
Industry
136.29%
Market
70.65%
BDTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BDTX forecast to generate an efficient return on assets?

Company
-64.18%
Industry
22.71%
BDTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BDTX earnings per share forecast

What is BDTX's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$1.30
Avg 2 year Forecast
-$1.22
Avg 3 year Forecast
-$1.45

BDTX revenue forecast

What is BDTX's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$19.5M
Avg 2 year Forecast
$33.1M
Avg 3 year Forecast
$128.2M

BDTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BDTX$2.41$15.50+543.15%Strong Buy
RPTX$3.15$10.00+217.46%Buy
IVA$2.65$11.00+315.09%Buy
MCRB$0.82$5.63+583.48%Strong Buy
NBTX$3.00$12.00+300.00%Strong Buy
View Top Biotech Stocks

Black Diamond Therapeutics Stock Forecast FAQ

Is Black Diamond Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: BDTX) stock is to Strong Buy BDTX stock.

Out of 4 analysts, 1 (25%) are recommending BDTX as a Strong Buy, 3 (75%) are recommending BDTX as a Buy, 0 (0%) are recommending BDTX as a Hold, 0 (0%) are recommending BDTX as a Sell, and 0 (0%) are recommending BDTX as a Strong Sell.

If you're new to stock investing, here's how to buy Black Diamond Therapeutics stock.

What is BDTX's earnings growth forecast for 2024-2026?

(NASDAQ: BDTX) Black Diamond Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.72%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.31%.

Black Diamond Therapeutics's earnings in 2024 is -$73,099,000.On average, 7 Wall Street analysts forecast BDTX's earnings for 2024 to be -$73,560,582, with the lowest BDTX earnings forecast at -$75,823,984, and the highest BDTX earnings forecast at -$70,165,478. On average, 7 Wall Street analysts forecast BDTX's earnings for 2025 to be -$69,197,874, with the lowest BDTX earnings forecast at -$109,209,172, and the highest BDTX earnings forecast at -$46,399,752.

In 2026, BDTX is forecast to generate -$82,274,682 in earnings, with the lowest earnings forecast at -$139,765,106 and the highest earnings forecast at -$43,570,499.

What is BDTX's revenue growth forecast for 2026-2028?

(NASDAQ: BDTX) Black Diamond Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.88%.

Black Diamond Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast BDTX's revenue for 2026 to be $1,101,711,177, with the lowest BDTX revenue forecast at $1,101,711,177, and the highest BDTX revenue forecast at $1,101,711,177. On average, 4 Wall Street analysts forecast BDTX's revenue for 2027 to be $1,870,702,183, with the lowest BDTX revenue forecast at $1,000,989,764, and the highest BDTX revenue forecast at $3,954,730,053.

In 2028, BDTX is forecast to generate $7,256,355,309 in revenue, with the lowest revenue forecast at $3,104,822,407 and the highest revenue forecast at $14,713,248,081.

What is BDTX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: BDTX) forecast ROA is -64.18%, which is lower than the forecast US Biotechnology industry average of 22.71%.

What is BDTX's Price Target?

According to 4 Wall Street analysts that have issued a 1 year BDTX price target, the average BDTX price target is $15.50, with the highest BDTX stock price forecast at $20.00 and the lowest BDTX stock price forecast at $11.00.

On average, Wall Street analysts predict that Black Diamond Therapeutics's share price could reach $15.50 by Nov 6, 2025. The average Black Diamond Therapeutics stock price prediction forecasts a potential upside of 543.15% from the current BDTX share price of $2.41.

What is BDTX's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: BDTX) Black Diamond Therapeutics's current Earnings Per Share (EPS) is -$1.33. On average, analysts forecast that BDTX's EPS will be -$1.30 for 2024, with the lowest EPS forecast at -$1.34, and the highest EPS forecast at -$1.24. On average, analysts forecast that BDTX's EPS will be -$1.22 for 2025, with the lowest EPS forecast at -$1.93, and the highest EPS forecast at -$0.82. In 2026, BDTX's EPS is forecast to hit -$1.45 (min: -$2.47, max: -$0.77).

What is BDTX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: BDTX) forecast ROE is -90.84%, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.